MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$421.19M, compared with -$221.71M a year earlier.
Context
- Retained earnings amounted to 100.6% of total assets at the end of Q1 FY2026, down 98.1 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -90.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (360.52M) USD
- Year-over-year change
- -80.8%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (360.52M) | -80.8% |
| FY2024 | 2024-12-31 | (199.37M) | -63.7% |
| FY2023 | 2023-12-31 | (121.79M) | -84.3% |
| FY2022 | 2022-12-31 | (66.08M) | — |
Retained Earnings vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's Mar 2026 retained earnings of -$421.19M is the 8th highest of the 11 companies compared; the peer median is -$361.44M.
- Its year-over-year change of -90.0% is the 10th highest of 11, against a peer median of -38.9%.
- Retained earnings amounts to 100.6% of total assets for MPLT, versus a peer median of 81.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | -$148.58M | -29.8% | — | 37.8% |
| Mar 2026 | -$173.23M | -48.0% | — | 62.9% | |
| Mar 2026 | -$227.87M | -48.4% | — | 82.5% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | -$255.09M | -72.6% | — | 51.3% |
| Mar 2026 | -$338.7M | -7.7% | — | 150.1% | |
| Mar 2026 | -$384.17M | +24.4% | — | 137.9% | |
| Dec 2025 | -$388.13M | -11.5% | — | 291.9% | |
| Mar 2026 | -$421.19M | -90.0% | — | 100.6% | |
| Jun 2026 | -$796.74M | -98.0% | — | 0.8% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | -$869.72M | -63.4% | — | 81.0% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | -$1.24B | -21.9% | — | 804.3% |
| Peer median (excluding MPLT) | -$361.44M | -38.9% | — | 81.7% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.